Search company, investor...

Predict your next investment

Amgen company logo
Corporation
HEALTHCARE | Biotechnology
amgen.com

See what CB Insights has to offer

Investments

8

Partners & Customers

10

Service Providers

1

About Amgen

Amgen (NASDAQ: AMGN) is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering human therapeutics. Amgen focuses on areas of high unmet medical need and leverages their biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. The company was founded in 1980 and is based in Thousand Oaks, California.

Headquarters Location

One Amgen Center Drive

Thousand Oaks, California, 91320,

United States

805-447-1000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Amgen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Amgen in 2 Expert Collections, including Diabetes.

D

Diabetes

1,899 items

M

Medical Devices

485 items

https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.

Amgen Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Amgen Rank

Research containing Amgen

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Amgen in 1 CB Insights research brief, most recently on Oct 28, 2022.

Latest Amgen News

insitro Appoints Philip Tagari as Chief Scientific Officer

Dec 2, 2022

Tagari joins insitro from Amgen, where he led the discovery of multiple important new therapies across therapeutic areas and modalities for more than two decades insitro, a machine learning-powered drug discovery and development company, today announced that Philip Tagari has been appointed as chief scientific officer. Tagari joins insitro following a... The post insitro Appoints Philip Tagari as Chief Scientific Officer first appeared on AI-TechPark.

Amgen Investments

8 Investments

Amgen has made 8 investments. Their latest investment was in Neumora as part of their Series B on October 10, 2022.

CBI Logo

Amgen Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/11/2022

Series B

Neumora

$112M

No

11

10/7/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/13/2020

Corporate Minority - P2P - II

Subscribe to see more

$99M

Subscribe to see more

10

10/31/2019

Corporate Minority - P2P

Subscribe to see more

$99M

Subscribe to see more

10

10/18/2018

Corporate Minority - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/11/2022

10/7/2021

7/13/2020

10/31/2019

10/18/2018

Round

Series B

Series A

Corporate Minority - P2P - II

Corporate Minority - P2P

Corporate Minority - II

Company

Neumora

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$112M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

11

10

10

10

10

Amgen Acquisitions

25 Acquisitions

Amgen acquired 25 companies. Their latest acquisition was ChemoCentryx on October 20, 2022.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/20/2022

Series D

$99M

$139.14M

Acq - P2P

3

7/27/2021

$99M

Acquired

10

4/16/2021

Other

$99M

$75M

Acq - P2P

14

3/30/2021

Series B

Subscribe to see more

$99M

$99M

Subscribe to see more

10

11/22/2019

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/20/2022

7/27/2021

4/16/2021

3/30/2021

11/22/2019

Investment Stage

Series D

Other

Series B

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

$139.14M

$75M

$99M

Note

Acq - P2P

Acquired

Acq - P2P

Subscribe to see more

Subscribe to see more

Sources

3

10

14

10

10

Amgen Partners & Customers

10 Partners and customers

Amgen has 10 strategic partners and customers. Amgen recently partnered with Direct Relief on October 10, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

10/19/2022

Partner

United States

1

10/11/2022

Partner

United States

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen's LUMAKRAS® (sotorasib)

These forward-looking statements , including statements relating to expectations , plans , and prospects regarding the success of our non-exclusive clinical collaboration with Amgen Inc. , the timing and success of our Phase 1/2 study to evaluate the safety and preliminary efficacy of BBP-398 in combination with LUMAKRAS in patients with advanced solid tumors with the KRAS G12C mutation , including the potential availability of initial data at the end of 2024 , the US Food and Drug Administration 's grant of Fast Track designation for the investigation of BBP-398 in combination with LUMAKRAS for adult patients with previously treated , KRAS , metastatic NSCL , the ability of combining SHP2 inhibition with KRAS G12C inhibition in patients with the KRAS G12C mutation to prevent oncogenesis and overactive cellular proliferation , the availability of initial Phase 1 data from the ongoing BBP-398 trial expected in 2023 , our ability to provide substantial relief for cancer patients in need , the promise of targeted therapies for patients with KRAS mutations , the success and status of current and future relationships with third-party collaborators and academic partners , the continuing success of our clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398 with OPDIVO ® , and the potential ability of our product candidates to treat genetically driven diseases and cancers with clear genetic drivers , reflect our current views about our plans , intentions , expectations , strategies and prospects , and are based on the information currently available to us and on assumptions we have made and are not forecasts , promises nor guarantees .

2

6/7/2022

Licensee

South Korea

Amgen, Jeil Pharm to co-promote cholesterol reducer Repatha

Amgen and Jeil Pharmaceutical said they signed an agreement to jointly sell Repatha , lipid-lowering drugs for atherosclerotic cardiovascular disease and hypercholesterolemia starting in June .

1

3/10/2022

Vendor

United States

Subscribe to see more

Subscribe to see more

10

2/17/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

10/19/2022

10/11/2022

6/7/2022

3/10/2022

2/17/2022

Type

Partner

Partner

Licensee

Vendor

Partner

Business Partner

Country

United States

United States

South Korea

United States

United States

News Snippet

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen's LUMAKRAS® (sotorasib)

These forward-looking statements , including statements relating to expectations , plans , and prospects regarding the success of our non-exclusive clinical collaboration with Amgen Inc. , the timing and success of our Phase 1/2 study to evaluate the safety and preliminary efficacy of BBP-398 in combination with LUMAKRAS in patients with advanced solid tumors with the KRAS G12C mutation , including the potential availability of initial data at the end of 2024 , the US Food and Drug Administration 's grant of Fast Track designation for the investigation of BBP-398 in combination with LUMAKRAS for adult patients with previously treated , KRAS , metastatic NSCL , the ability of combining SHP2 inhibition with KRAS G12C inhibition in patients with the KRAS G12C mutation to prevent oncogenesis and overactive cellular proliferation , the availability of initial Phase 1 data from the ongoing BBP-398 trial expected in 2023 , our ability to provide substantial relief for cancer patients in need , the promise of targeted therapies for patients with KRAS mutations , the success and status of current and future relationships with third-party collaborators and academic partners , the continuing success of our clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398 with OPDIVO ® , and the potential ability of our product candidates to treat genetically driven diseases and cancers with clear genetic drivers , reflect our current views about our plans , intentions , expectations , strategies and prospects , and are based on the information currently available to us and on assumptions we have made and are not forecasts , promises nor guarantees .

Amgen, Jeil Pharm to co-promote cholesterol reducer Repatha

Amgen and Jeil Pharmaceutical said they signed an agreement to jointly sell Repatha , lipid-lowering drugs for atherosclerotic cardiovascular disease and hypercholesterolemia starting in June .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

1

10

10

Amgen Service Providers

1 Service Provider

Amgen has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acquired

Counsel

General Counsel

Service Provider

Associated Rounds

Acquired

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Amgen Team

38 Team Members

Amgen has 38 team members, including current Managing Director, Janis Naeve.

Name

Work History

Title

Status

Janis Naeve

Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Janis Naeve

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Managing Director

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Compare Amgen to Competitors

B
BRAVIS

BRAVIS is a software and system house. It develops high-end internet-based video conference systems.

A
AbbVie

AbbVie (NYSE: ABBV) researches and develops pharmaceutical products. The company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women's health, oncology, and neuroscience. It also offers treatments for diseases including multiple sclerosis, Parkinson's, and Alzheimer's disease. The company was founded in 2013 and is based in North Chicago, Illinois.

H
HAPLN Science

HAPLN Science is a drug development company that focuses on anti-aging therapies that can reverse tissue and organ degeneration. The company's products include treatments for degenerative arthritis, skin aging treatment, hair loss, and connective tissue disease. HAPLN Science was founded in 2018 and is based in Seongnam, South Korea.

Pfizer Logo
Pfizer

Pfizer (NYSE: PFE) offers a diversified health care portfolio including human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer products. It works across various markets to promote wellness, prevention, treatments, and cures that challenge feared diseases. The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. The company was founded in 1849 and is based in New York, New York.

FoodMarble Logo
FoodMarble

FoodMarble has developed a personal digestive tracker. Based on validated clinical technology, this tiny breath test device and app can be used with the help of AI to help people work out what foods are most compatible with their unique digestive system.

Syntr Health Technologies Logo
Syntr Health Technologies

Syntr Health Technologies specializes in the micro fragmentation of adipose tissue for body contouring. The company was founded in 2016 and is based in Irvine, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.